Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation

被引:132
作者
Anderson, K
Jacobson, JS
Heitjan, DF
Zivin, JG
Hershman, D
Neugut, AI
Grann, VR
机构
[1] Columbia Univ, Joseph L Mailman Sch Publ Hlth, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[2] New York Presbyterian Hosp, New York, NY USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-144-6-200603210-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For BRCA1 or BRCA2 mutation carriers, decision analysis indicates that prophylactic surgery or chemoprevention leads to better survival than surveillance alone. Objective: To evaluate the cost-effectiveness of the preventive strategies that are available to unaffected women carrying a single BRCA1 or BRCA2 mutation with high cancer penetrance. Design: Markov modeling with Monte Carlo simulations and probabilistic sensitivity analyses. Data Sources: Breast and ovarian cancer incidence and mortality rates, preference ratings, and costs derived from the literature; the Surveillance, Epidemiology, and End Results (SEER) Program; and the Health Care Financing Administration (now the Centers for Medicare & Medicaid Services). Target Population: Unaffected carriers of a single BRCA1 or BRCA2 mutation 35 to 50 years of age. Time Horizon: Lifetime. Perspective: Health policy, societal. Interventions: Tamoxifen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or surveillance. Outcome Measures: Cost-effectiveness. Results of Base-Case Analysis: For mutation carriers 35 years of age, both surgeries (prophylactic bilateral mastectomy and oophorectomy) had an incremental cost-effectiveness ratio over oophorectomy alone of $2352 per life-year for BRCA1 and $100 per life-year for BRCA2. With quality adjustment, oophorectomy dominated all other strategies for BRCA1 and had an incremental cost-effectiveness ratio of $2281 per life-year for BRCA2. Results of Sensitivity Analysis: Older age at intervention increased the cost-effectiveness of prophylactic mastectomy for BRCA1 mutation carriers to $73 755 per life-year. Varying the penetrance, mortality rates, costs, discount rates, and preferences had minimal effects on outcomes. Limitations: Results are dependent on the accuracy of model assumptions. Conclusion: On the basis of this model, the most cost-effective strategies for BRCA mutation carriers, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively.
引用
收藏
页码:397 / 406
页数:10
相关论文
共 70 条
[11]  
COUCH FJ, 1998, GENETIC BASIS HUMAN, P549
[12]  
Cuzick J, 2002, LANCET, V360, P817
[13]  
DeVita VT., 1997, CANC PRINCIPLES PRAC, V5th
[14]  
Easton DF, 2004, SCIENCE, V306, P2187
[15]   SCREENING FOR CERVICAL-CANCER [J].
EDDY, DM .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (03) :214-226
[16]   Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer [J].
Eisen, A ;
Rebbeck, TR ;
Wood, WC ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) :1980-1995
[17]   Oral contraceptives and venous thromboembolic disease: The findings from database studies in the United Kingdom and Germany [J].
Farmer, RDT ;
Lawrenson, RA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (03) :S78-S86
[18]  
Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51
[19]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[20]   National surgical adjuvant breast and bowel project breast cancer prevention trial: A reflective commentary [J].
Fisher, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1632-1639